Could Bio-path Holdings Inc (NASDAQ:BPTH) Go Up After Its Newest Short Interest Report?

May 18, 2018 - By Matt Thomas

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Logo

Investors sentiment increased to 1.43 in 2017 Q4. Its up 0.82, from 0.61 in 2017Q3. It is positive, as 0 investors sold Bio-Path Holdings, Inc. shares while 7 reduced holdings. 4 funds opened positions while 6 raised stakes. 12.58 million shares or 18.70% more from 10.60 million shares in 2017Q3 were reported.
Moreover, Hightower Limited Com has 0% invested in Bio-Path Holdings, Inc. (NASDAQ:BPTH) for 60,000 shares. Deutsche Comml Bank Ag owns 223 shares for 0% of their portfolio. Bnp Paribas Arbitrage owns 20 shares for 0% of their portfolio. 1,995 were reported by Bankshares Of Montreal Can. State Street Corporation has invested 0% in Bio-Path Holdings, Inc. (NASDAQ:BPTH). Meeder Asset Mgmt holds 0% or 6,592 shares in its portfolio. Vanguard holds 0% or 1.91 million shares. University Of Texas Inv Managment reported 3.83M shares or 2.96% of all its holdings. Geode Mgmt Lc holds 0% of its portfolio in Bio-Path Holdings, Inc. (NASDAQ:BPTH) for 524,570 shares. Two Sigma Securities Llc has 0% invested in Bio-Path Holdings, Inc. (NASDAQ:BPTH) for 35,036 shares. Royal Bank & Trust Of Canada stated it has 838 shares or 0% of all its holdings. Blackrock has invested 0% in Bio-Path Holdings, Inc. (NASDAQ:BPTH). Morgan Stanley reported 0% of its portfolio in Bio-Path Holdings, Inc. (NASDAQ:BPTH). Moreover, Bank & Trust Of America De has 0% invested in Bio-Path Holdings, Inc. (NASDAQ:BPTH) for 9,300 shares. Bancorporation Of Mellon Corporation holds 0% or 123,400 shares in its portfolio.

The stock of Bio-path Holdings Inc (NASDAQ:BPTH) registered an increase of 5.88% in short interest. BPTH’s total short interest was 546,000 shares in May as published by FINRA. Its up 5.88% from 515,700 shares, reported previously. With 224,400 shares average volume, it will take short sellers 2 days to cover their BPTH’s short positions.

The stock increased 0.57% or $0.01 during the last trading session, reaching $1.75. About 500 shares traded. Bio-Path Holdings, Inc. (NASDAQ:BPTH) has declined 76.76% since May 18, 2017 and is downtrending. It has underperformed by 88.31% the S&P500.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development firm in the United States. The company has market cap of $19.85 million. The firm develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid backbone modification intended to protect the DNA from destruction. It currently has negative earnings. The Company’s lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer.

More notable recent Bio-Path Holdings, Inc. (NASDAQ:BPTH) news were published by: Streetinsider.com which released: “Pre-Open Movers 04/19 (BPTH) (GWW) (AMZN) Higher; (ACET) (HMNY) (SNBR) (PIR) Lower (more…)” on April 19, 2018, also Globenewswire.com with their article: “Bio-Path Holdings Reports First Quarter 2018 Financial Results” published on May 16, 2018, Nasdaq.com published: “Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board” on May 10, 2018. More interesting news about Bio-Path Holdings, Inc. (NASDAQ:BPTH) were released by: Seekingalpha.com and their article: “Bio-Path Holdings’ (BPTH) CEO Peter Nielsen on Q1 2018 Results – Earnings Call Transcript” published on May 16, 2018 as well as Benzinga.com‘s news article titled: “Earnings Scheduled For May 16, 2018” with publication date: May 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: